4 months ago
LLY
AnalystsEmily FieldEmily Field's Stock Forecasts
AnalystsEmily Field
Sectors:
Industries:
Analyst Ranking
Top 38%
#2073 out of 5510 analysts
Average Return
+9.57%
Win Rate
80%8 out of 10
Risk vs Reward
Poor
Good
Emily Field's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Argenx SeARGX | +27.02% | $295.58 | $375.44 | 2021-10-19 - 2022-10-18 | Strong Buy |
Merck & Co IncMRK | +20.67% | $122.26 | $147.53 | 2026-02-20 - 2026-09-09 | Strong Buy |
Eli Lilly & CoLLY | +13.69% | $988.87 | $1,124.21 | 2026-05-05 - 2026-09-09 | Strong Buy |
Merck & Co IncMRK | +13.17% | $130.36 | $147.53 | 2026-07-29 - 2026-09-09 | Strong Buy |
Abbvie IncABBV | +11.61% | $224.81 | $250.91 | 2026-02-20 - 2026-09-09 | Strong Buy |
Emily Field Analyst Color
Get additional color on Emily Field's coverage of popular stocks
7 months ago
MRK
7 months ago
LLY
Emily Field's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Amgen IncAMGN | 3 | Hold | $380.00 | -2.88% | Maintains | a month ago |
Cytokinetics IncCYTK | 1 | Strong Buy | $110.00 | +48.43% | Maintains | a month ago |
Merck & Co IncMRK | 2 | Strong Buy | $150.00 | +1.67% | Maintains | a month ago |
Gilead Sciences IncGILD | 2 | Hold | $145.00 | -0.45% | Maintains | a month ago |
Biogen IncBIIB | 2 | Hold | $200.00 | -5.09% | Maintains | a month ago |
Abbvie IncABBV | 2 | Strong Buy | $300.00 | +19.56% | Maintains | a month ago |
Eli Lilly & CoLLY | 2 | Strong Buy | $1,400.00 | +24.53% | Maintains | 4 months ago |
Pfizer IncPFE | 1 | Strong Sell | $25.00 | -10.01% | Initiates Coverage On | 7 months ago |
Bristol Myers Squibb CoBMY | 1 | Strong Buy | $75.00 | +16.44% | Initiates Coverage On | 7 months ago |
Novo Nordisk A SNVO | 1 | Hold | N/A | N/A | Downgrades | a year ago |
Gsk PLCGSK | 1 | Hold | N/A | N/A | Upgrades | 5 years ago |
Argenx SeARGX | 1 | Strong Buy | N/A | N/A | Upgrades | 5 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.